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Summary
Introduction: Pediatric obesity is a major health concern in the United States
and as many as 34% of those who require general anesthesia are overweight
or obese (OW). The lack of data and recommendations for dosing medica-
tions in obese children leaves significant gaps in the understanding of correct
dosing in the clinical setting.
Objective: To determine whether OW children were more likely to receive
doses of medications outside the recommended range.
Methods: Following IRB approval, patient medical records were queried to
identify children 2 through 17 years who underwent noncardiac surgeries and
received at least one medication of interest. Children with hepatic disease,
renal disease, neurological impairment, sleep-disordered breathing, or missing
height or weight measurements were excluded. Children were stratified into
weight categories based on age and gender percentiles as per CDC guidelines.
Those ≥85th percentile were classified as overweight/obese. Ideal and lean
weight (for age, gender) were calculated. Drug doses were stratified as under-
dosed (>10% below minimum recommended dose), overdosed (>10% above
maximum recommended dose), or within recommended dose (dose  10%).
Actual doses were compared to recommended doses as per actual, ideal, or
lean weight (as recommended for specific drugs) in the overweight/obese
groups vs the control weight (CW) group.
Results: Ten thousand five hundred and nine doses were reviewed. Over-
weight/obese children were more likely to receive doses outside the recom-
mended dose range than the CW group.
Conclusions: Overweight/obese children were more likely to receive doses of
common anesthetic medications outside the recommended doses potentially
adding risk of adverse outcomes in these children.
Introduction
Pediatric obesity is a major public health concern in the
United States (1), with up to 34% of school-age children
and adolescents being overweight [body mass index
(BMI) ≥85th percentile] or obese (BMI ≥95th percen-
tile). Indeed, childhood obesity prevalence has increased
up to threefold over the last three decades (1,2). Recent
Centers for Disease Control and Prevention (CDC) data
(2010) suggest that a slight decrease in obesity and mor-
bid obesity in poor, preschool, nonnative American or
Alaskan populations have decreased slightly during the
previous 7 years (3). However, obesity continues to be a
troubling attribute of America’s young people. Further-
more, more than 30% of pediatric patients presenting
for surgery in one large pediatric setting were found
to be overweight or obese (OW) (4). These trends sug-
gest a need to address specific healthcare needs of this
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population. Of particular concern is the potential lack
of understanding regarding how to safely and effectively
dose medications for OW children.
The absence of age and weight appropriate pharma-
cokinetic (PK) and pharmacodynamics (PD) data and
pediatric labeling has led to ‘off-label’ the use of most
drugs that are administered to children (5,6), and has
left dosing practices at the discretion and experience of
the care provider. Although such dosing involves admin-
istering drugs to children based on lean body weight
(LBW), actual body weight (ABW), or ideal body
weight (IBW), no single approach is thought to cover all
circumstances (7). The variable recommendations for
dosing different medications may lead to inconsistencies
in actual dosing practices, leaving children at risk of
under- or overdosing. This risk may be greater for
children who are OW.
In the perioperative setting, inappropriate dosing may
contribute to ineffective pain treatment, infection pro-
phylaxis, and other outcomes, which may negatively
impact the quality and cost of patient care. Indeed, find-
ings in adult studies have exposed potential risks for
obese patients who received inappropriate dosing of
anticoagulants and antibiotics (8,9). It remains
unknown whether similar risks are posed by potentially
inappropriate dosing practices in the pediatric setting.
This study therefore examined whether actual doses of
commonly used medications were administered outside
the recommended dose range to children who were OW
by anesthesia care providers. Such data are needed to
identify potentially ineffective dosing practices for
children in this weight group.
The aim of the study was to determine whether chil-
dren who are OW were at greater risk of receiving doses
outside recommended doses compared to control weight
(CW) (all children studied outside the OW group)
children. We hypothesized that (i) OW children would
more often receive medication doses outside the recom-
mended ranges compared to children in the CW group;
and (ii) OW children have a lower probability of being
overdosed with medications dosed on actual weight
(RDAW) than children in CW group.
Methods
Following Institutional Review Board approval and
waiver of consent, this study included data retrospec-
tively retrieved from the electronically captured anesthe-
sia records (Centricity; GE Healthcare Information
Technologies, Milwaukee, WI, USA). Data were
included only for children aged 2 through 17 years who
underwent anesthesia and received a single dose only of
at least one of the commonly used medications of
interest for a noncardiac procedure between February
2006 and May 2011. Children who remained intubated
beyond the operating room setting or who had a history
of hepatic or renal disease, neurological impairment, or
sleep disordered breathing were excluded. In addition,
patients without essential data (i.e., height or weight
measurements) or who had unverifiable extreme height
or weight data were excluded.
Medication categories
For this study, we focused on a few commonly used
drugs from categories of agents that have data support-
ing recommended dosing based on ideal body weight
(RDIW), actual body weight (RDAW), or lean body
weight (RDLW). These classifications were based on
limited pediatric drug dosing studies or recommenda-
tions or, more commonly, data from adult studies and
expert interpretation of combined sources. Based on
these limited recommendations, doses of midazolam and
morphine were classified as RDIW (10–12) succinylcho-
line and neostigmine, as RDAW (11–15) and cisatracuri-
um, and as RDLW (16).
Recommended dose ranges (see Table 4, Medication
column) were calculated for each of these agents, and
the actual doses administered were compared to these in
the analyses. These actual dosing outcomes were defined
as follows:
• Recommended dose: any dose between the minimum
recommended dose for the agent less 10% and the
maximum recommended dose plus 10%.
• Under-dose: any dose administered more than 10%
below the minimum recommended dose.
• Overdose: any dose administered more than 10%
above the maximum recommended.
Weight categories
Body mass index was calculated using the weight and
height of each patient based on the standard formula
(i.e., BMI = Wgt(kg)/(Ht(m)2). Based on age- and gen-
der-specific Centers for Disease Control and Prevention
(CDC) growth charts,1 children were included in the
control group if they were below or equal to the 85th
percentile, and in the OW group if above the 85th per-
centile. The medical records of children with docu-
mented BMI over the 85th percentile for age/gender
were reviewed to ensure the accuracy of these classifica-
tions. Unverifiable data were excluded. Ideal body
weight was determined by BMI method. Essentially, this
1www.cdc.gov/obesity/childhood/defining.html.
© 2014 John Wiley & Sons Ltd
Pediatric Anesthesia 24 (2014) 857–862
858
Medication dosing in overweight children C.N. Burke et al.
method relates a child’s actual BMI to the 50th percen-
tile for age and gender on the CDC growth charts, which
is considered their ideal body weight (17). Lean body
weight defined as total body weight minus fat, expressed
in kilograms was calculated using the formula
3.8 9 (0.0215 9 W0.65 9 H0.72) (18, 19).
Statistical analysis
Data analyses were performed with IBM SPSS Statistics
for Windows, (Version 20.0, Armonk, NY, USA). All
parametric data (e.g., age) are described as means  SD,
and nonparametric data (e.g., gender) as n (%). Chi-
square analyses were used to compare dosing outcomes
(i.e., overdose or under-dose) between weight groups
(i.e., OW vs CW). Odds ratios and 95% confidence
intervals were calculated for all comparisons.
Results
The sample included data from 10 498 patients; their
demographic characteristics are shown in Table 1 and
the number of doses of each agent administered to the
study groups is shown in Table 2. Overall, OW children
had a 30% lower odds of receiving a recommended dose
of any medication compared to the control group (see
Table 3). Figure 1 depicts the number of children in
each weight classification by age.
Table 4 describes the proportion of children in each
weight group who received under- or overdoses with the
agents in each drug category. Compared to children in
the CW group who were administered morphine, those
in the OW group were 3.5 times more likely to have
received an overdose and nearly 70% less likely to have
received an under-dose. Furthermore, the OW group
had a significantly higher odds of receiving under-doses
of succinylcholine and neostigmine.
Discussion
This study is the first to demonstrate that OW children
have a significant risk of receiving doses of commonly
used anesthetic medications outside the recommended
doses. Casati stated that administering medications on
total weight irrespective of recommendations may result
in under- or overdosing and inappropriate dosing may
contribute to ineffective treatment or potentiate adverse
events (20). Consistent with our hypotheses, we found
children in the OW group had a greater odds of being
dosed with medications outside their recommended
ranges. These findings suggest that children who are
OW are potentially at greater risk of medication ineffec-
tiveness or adverse events.
Table 1 Characteristics of the sample
n = 10 498
Age in years (2 through 17) 9.7  4.7
BMI 19.8  5.7 [4.2–69.6]
Weight groups Male/Female
Control group 4258 (40)/3158 (30)
Overweight/Obese group 1545 (15)/1537 (15)
BMI, body mass index.
Data presented as mean  SD, [range], and n (%).
Table 2 Weight group distribution for medications
Medication
total doses (n = 10 509) Control Overweight/Obese
Midazolam (1139) 771 (68) 368 (32)
Morphine (3418) 2480 (73) 938 (27)
Cisatracurium (1670) 1145 (69) 525 (31)
Neostigmine (3600) 2477 (69) 1123 (31)
Succinylcholine (682) 415 (61) 267 (39)
Data presented as n (%).
Table 3 Overall dosing comparisons between groups
Control
group
(n = 7288)
OW group
(n = 3221) OR [CI]; P value
Under-dosed 2317 (32) 1232 (38) 1.33 [1.22–1.45]; <0.001
Recommended
dose
4717 (65) 1799 (56) 0.69 [0.64–0.75]; <0.001
Overdosed 264 (4) 189 (6) 1.78 [1.46–2.2]; <0.001
OW, overweight or obese.
Data presented as n (%); odds ratio [95% confidence interval].
Odds ratios calculated with the ‘recommended dose’ as the refer-
ence group.
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Figure 1 Number of children per weight classification by age.
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Of particular concern was the finding that children
in the OW group were more likely to have received a
dose of morphine that exceeded the recommended
dose range for that agent. Excessive dosing of opioids
may increase the risk of opioid-related respiratory
depression and airway obstruction, which may be
higher in children with obesity even when given in
recommended doses (21–23). The known alterations in
body make-up and physiology secondary to obesity
(e.g., cardiac dysfunction, plasma protein concentra-
tion abnormalities, nonalcoholic steatohepatitis) nega-
tively impact the utilization and clearance of
medications (24). Findings from a recent study in nor-
mal weight and obese adults suggested differences in
the clearance of fentanyl between lean and obese
patients and further showed that dosing should be
based on pK mass (i.e., LBW). The investigation con-
cluded that lean dosing corrections may apply to dos-
ing for other drugs in obese patients as well (25).
These characteristics in conjunction with the variable
growth and organ maturation phases throughout
childhood (12,26,27) make the obese child particularly
vulnerable to adverse effects of medications, even
when received in recommended doses. Doses that are
in excess of those recommended, such as demon-
strated for morphine in this study, may further
increase these risks. Further study is needed to exam-
ine the potential consequences of dosing these agents
in vulnerable children.
Obese and overweight children may also be suscep-
tible to receiving ineffective doses of medications. Our
data suggest that this may be particularly so for
agents such as neostigmine and succinylcholine, which
are recommended to be given based on actual weight.
Our results indicate OW children were nearly twice as
likely to receive an under-dose of these medications.
This is concerning as under-dosing muscle relaxants
may lead to motor activity, providing suboptimal con-
ditions for endotracheal intubation or jeopardizing the
integrity of the surgery. Under-dosing a reversal agent
may subject a patient to inadequate ventilation due to
prolonged neuromuscular blockade. Interestingly,
Lemmens and Brodsky demonstrated that the onset
time of maximum blockade in adults was the same
whether the dose of succinylcholine was calculated on
actual, ideal, or lean body weight. However, intubat-
ing conditions were rated as poor, significantly more
often in the ideal or lean body weight calculation
groups (28). In addition, Suzuki, et al. (29) found that
spontaneous recovery from neuromuscular blocking
agents is significantly longer in overweight and obese
than normal weight females. Although our data do
not explain why children were under-dosed, it is possi-
ble, given the paucity of PK and PD data and dosing
recommendations for children, that clinicians may
have been uncomfortable administering doses that
seem to be excessive compared to those usually
administered in the general population of normal
weight children. If children behave in similar fashion,
the implications of prolonged paralysis or incomplete
reversal may be troublesome. Our data suggest that
clinicians’ actual dosing practices appear to regress to
Table 4 Comparison of specific dosing outcomes in the study groups
Medication
[Recommended
dose range]
Under-dosed Overdosed
Control OW
OR [95% CI];
P value Control OW
OR [95% CI];
P value
Recommended dose per ideal weight (kg I)
Midazolam
[0.05–0.1 mgkg I1]
545 (71)
32.1 [33 to 31]
246 (67)
33 [34 to 31.5]
0.8 [0.6 to 1.1];
0.19
21 (3)
54 [29.5 to 79]
14 (3.8)
59 [40 to 79]
1.4 [0.7 to 2.8];
0.32
Morphine
[0.025–0.1 mgkg I1]
166 (7)
28 [30 to 26]
21 (2)
31 [36 to 26]
0.3 [0.2 to 0.5];
0.00
136 (6)
28 [25 to 32]
157 (17)
43 [38 to 48]
3.5 [2.7 to 4.4];
0.00
Recommended dose per actual weight (kg A)
Neostigmine
[0.05–0.08 mgkg
A1]
1335 (54)
30 [31 to 30]
752 (67)
36 [37 to 35]
1.7 [1.5 to 2.0];
0.00
19 (0.8)
28 [19 to 36.5]
5 (0.4)
27 [10.7 to 43]
0.6 [0.2 to 1.6];
0.27
Succinylcholine
[1–2 mgkg A1]
39 (9)
47 [56 to 38]
44 (17)
36 [44 to 29]
2 [1.2 to 3.0];
0.006
20 (5)
32 [18 to 45]
5 (2)
29 [110 to 167]
0.4 [0.1 to 1.01];
0.059
Recommended dose per lean weight (kg L)
Cisatracurium
[0.1–0.2 mgkg L1]
125 (10.9)
32 [35 to 29]
60 (11.4)
34 [39 to 28]
1.1 [0.8 to 1.5];
0.76
181 (15.8)
31 [28 to 34]
76 (14.5)
31 [26 to 36]
0.9 [0.7 to 1.2];
0.49
Data are presented as the n (%) of the group (i.e., control or OW) that were under-dosed or overdosed with the agent shown and as n (%); per-
cent difference from recommended dose expressed as mean [95% CI].
OW, overweight or obese. Bold values denote statistical significance.
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giving mean doses that fall within a recommended
range for CW children. It remains unknown how
these actual dosing practices may have affected out-
comes in children in these groups.
Limitations
The retrospective nature of this study and the use of
electronic data capture introduce the potential for
reporting bias, as well as a selection bias. It is possible
that patients were misclassified into weight groups given
the known documentation errors that can occur.
Although we attempted to minimize the potential for
error by verifying the weights, heights, and BMI of all
children in the extreme weight groups, it remains possi-
ble that some children were misclassified. Additionally,
we cannot dismiss the potential for error in the docu-
mented doses administered. Such error may have led to
a selection bias, where patients who received some of
these agents were excluded. Next, we classified medica-
tions into dosing groups and defined their recommended
doses based on the limited available data for children
and from extrapolated data regarding their chemical
properties, drug metabolism, and clearance in adults.
Most of these data were conducted in healthy, normal
weight populations (5,30,31). It remains unknown how
these data apply to normal vs overweight and obese chil-
dren, particularly in the absence of specific dosing rec-
ommendations. Additionally, we treated the obese
patients as a homogenous group even though children
who are clinically severely obese have a distinct physio-
logic profile that may have influenced dosing practices.
Furthermore, it is possible that actual doses adminis-
tered reflected personal experience, preferences, or
perhaps an individualization of care due to some
unknown patient characteristic. Future prospective
studies could explore dosing based on BMI categories.
Lastly, findings represent the dosing practices at one
institution where the attending anesthesiologists are
expert in the care of children, and may therefore not be
generalized to other settings. Our exclusion of patients
with conditions that are known to potentially influence
drug dosing may have eliminated some of these possibil-
ities, making the data more reflective of dosing practices
for the ‘average’ pediatric patient.
Conclusion
These data suggest that OW children may be susceptible
to receiving doses of commonly administered anesthetic
agents outside the recommended ranges. Such findings
may reflect the absence of pediatric dosing recommenda-
tions in general or for more specific guidelines for chil-
dren who are OW. It remains unknown whether or how
such dosing practices relate to anesthetic outcomes in
children.
This study identifies inconsistencies in dosing prac-
tices for children across weight classifications. This is
likely due to insufficient evidence to guide clinical deci-
sions regarding optimal dosing. Future research should
be directed at providing such an evidence base.
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